JP7539896B2 - Ｓｕｍｏ活性化酵素阻害剤及びチェックポイント阻害剤の投与 - Google Patents

Ｓｕｍｏ活性化酵素阻害剤及びチェックポイント阻害剤の投与 Download PDF

Info

Publication number
JP7539896B2
JP7539896B2 JP2021540127A JP2021540127A JP7539896B2 JP 7539896 B2 JP7539896 B2 JP 7539896B2 JP 2021540127 A JP2021540127 A JP 2021540127A JP 2021540127 A JP2021540127 A JP 2021540127A JP 7539896 B2 JP7539896 B2 JP 7539896B2
Authority
JP
Japan
Prior art keywords
administered
day
antibody
cancer
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021540127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022522328A5 (https=
JP2022522328A (ja
Inventor
サイ ムラリ クリシュナ プルクリ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2022522328A publication Critical patent/JP2022522328A/ja
Publication of JP2022522328A5 publication Critical patent/JP2022522328A5/ja
Application granted granted Critical
Publication of JP7539896B2 publication Critical patent/JP7539896B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021540127A 2019-02-27 2020-02-27 Ｓｕｍｏ活性化酵素阻害剤及びチェックポイント阻害剤の投与 Active JP7539896B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962811303P 2019-02-27 2019-02-27
US62/811,303 2019-02-27
PCT/US2020/020171 WO2020176772A1 (en) 2019-02-27 2020-02-27 Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors

Publications (3)

Publication Number Publication Date
JP2022522328A JP2022522328A (ja) 2022-04-18
JP2022522328A5 JP2022522328A5 (https=) 2023-03-06
JP7539896B2 true JP7539896B2 (ja) 2024-08-26

Family

ID=72238984

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021540127A Active JP7539896B2 (ja) 2019-02-27 2020-02-27 Ｓｕｍｏ活性化酵素阻害剤及びチェックポイント阻害剤の投与

Country Status (11)

Country Link
US (1) US12419890B2 (https=)
EP (1) EP3930719B1 (https=)
JP (1) JP7539896B2 (https=)
KR (1) KR20210131316A (https=)
CN (1) CN113473989B (https=)
AU (1) AU2020228385A1 (https=)
BR (1) BR112021016795A8 (https=)
CA (1) CA3128521A1 (https=)
MX (1) MX2021010176A (https=)
TW (1) TW202045175A (https=)
WO (1) WO2020176772A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021000349A (es) 2018-07-09 2021-05-14 Takeda Pharmaceuticals Co Administracion de un inhibidor de la enzima activadora de sumo y anticuerpos anti-cd20.
CA3128521A1 (en) 2019-02-27 2020-09-03 Millennium Pharmaceuticals, Inc. Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016540042A (ja) 2013-11-05 2016-12-22 コグネート バイオサービシズ， インコーポレイテッド がんを処置するためのチェックポイント阻害剤および治療薬の組合せ
JP2017524734A (ja) 2014-07-01 2017-08-31 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｓｕｍｏ活性化酵素の阻害薬として有用なヘテロアリール化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150071948A1 (en) * 2003-09-26 2015-03-12 Gregory Alan Lazar Novel immunoglobulin variants
AU2005235422B2 (en) * 2004-04-22 2011-08-11 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders II
BRPI0516132A (pt) 2004-10-07 2007-12-04 Vitae Pharmaceuticals Inc compostos, composição destes, método de antagonização de uma ou mais proteases aspárticas e método para tratar ou melhorar um distúrbio mediado por protease aspártica
ES2542884T3 (es) * 2008-09-23 2015-08-12 Rigel Pharmaceuticals, Inc. Inhibidores de JAK de carbamato tricíclico
WO2010044892A1 (en) 2008-10-17 2010-04-22 President And Fellows Of Harvard College Diagnostic method based on large scale identification of post-translational modification of proteins
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2012159782A1 (en) 2011-05-24 2012-11-29 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune High affinity sumo traps
CN105492429A (zh) 2013-07-02 2016-04-13 米伦纽姆医药公司 Sumo活化酶的杂芳基抑制剂
WO2015064532A1 (ja) * 2013-10-30 2015-05-07 第一三共株式会社 モルホリン化合物
TWI874834B (zh) * 2014-12-18 2025-03-01 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
NZ738406A (en) * 2015-06-11 2023-04-28 Bionomics Ltd Pharmaceutical combination of a tubulin polymerization inhibitor with an inhibitor of pd-l1, pd-1, or ctla-4 and uses and compositions thereof
US20190054090A1 (en) * 2015-10-01 2019-02-21 Gilead Sciences, Inc. Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
KR20180105685A (ko) 2016-02-08 2018-09-28 비욘드스프링 파마수티컬스, 인코포레이티드. 투카레솔 또는 이의 유사체를 함유하는 조성물
WO2018154529A1 (en) 2017-02-27 2018-08-30 Novartis Ag Dosing schedule for a combination of ceritinib and an anti-pd-1 antibody molecule
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
CA3128521A1 (en) 2019-02-27 2020-09-03 Millennium Pharmaceuticals, Inc. Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016540042A (ja) 2013-11-05 2016-12-22 コグネート バイオサービシズ， インコーポレイテッド がんを処置するためのチェックポイント阻害剤および治療薬の組合せ
JP2017524734A (ja) 2014-07-01 2017-08-31 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｓｕｍｏ活性化酵素の阻害薬として有用なヘテロアリール化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IGNACIO MELERO，EVOLVING SYNERGISTIC COMBINATIONS OF TARGETED IMMUNOTHERAPIES TO COMBAT CANCER，NATURE REVIEWS CANCER，英国，2015年07月24日，VOL:15，PAGE(S):457-472，http://dx.doi.org/10.1038/nrc3973

Also Published As

Publication number Publication date
US20220233531A1 (en) 2022-07-28
CN113473989A (zh) 2021-10-01
AU2020228385A1 (en) 2021-07-29
BR112021016795A8 (pt) 2022-08-16
CN113473989B (zh) 2024-03-08
US12419890B2 (en) 2025-09-23
CA3128521A1 (en) 2020-09-03
BR112021016795A2 (pt) 2021-10-19
JP2022522328A (ja) 2022-04-18
WO2020176772A1 (en) 2020-09-03
KR20210131316A (ko) 2021-11-02
EP3930719B1 (en) 2025-08-20
TW202045175A (zh) 2020-12-16
EP3930719A4 (en) 2022-11-23
EP3930719A1 (en) 2022-01-05
MX2021010176A (es) 2021-12-10

Similar Documents

Publication Publication Date Title
JP7122357B2 (ja) がんの治療のための方法、組成物、及びキット
US12403154B2 (en) Administration of sting agonist and checkpoint inhibitors
JP7352582B2 (ja) Ｓｕｍｏ活性化酵素阻害剤及び抗ｃｄ２０抗体の投与
JP7539896B2 (ja) Ｓｕｍｏ活性化酵素阻害剤及びチェックポイント阻害剤の投与
TW202233206A (zh) Ｓｔｉｎｇ促效劑、檢查點抑制劑及輻射之投與
RU2830077C2 (ru) Введение ингибитора sumo-активирующего фермента и ингибиторов контрольных точек
US20230218618A1 (en) Administration of sumo-activating enzyme inhibitor and anti-cd38 antibodies
WO2026053159A1 (en) Dazostinag or conjugates thereof for treatment of adenoid cystic carcinomas

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240416

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240716

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240814

R150 Certificate of patent or registration of utility model

Ref document number: 7539896

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150